# Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

> **NCT03095651** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 33 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** MK-5160 16 nmol/kg
- **BIOLOGICAL:** MK-5160 32 nmol/kg
- **BIOLOGICAL:** MK-5160 64 nmol/kg
- **BIOLOGICAL:** Glargine 0.4 U/kg
- **BIOLOGICAL:** Placebo to Glargine
- **BIOLOGICAL:** Placebo to MK-5160
- **DRUG:** Dextrose
- **BIOLOGICAL:** Glargine 0.6 U/kg

## Key facts

- **NCT ID:** NCT03095651
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-12
- **Primary completion:** 2018-01-30
- **Final completion:** 2018-01-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03095651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03095651, "Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03095651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*